Tongrun Biomedicine

Tongrun Biomedicine is a clinical-stage biotechnology company based in Suzhou, China, specializing in the discovery and development of novel antibody therapeutics for cancer. The company utilizes a proprietary platform to engineer bispecific antibodies designed to overcome resistance mechanisms in the tumor microenvironment. Its lead asset, TR009, is a bispecific antibody targeting both vascular endothelial growth factor (VEGF) and delta-like ligand 4 (DLL4), currently in Phase 1/2 clinical trials for advanced solid tumors. Tongrun's pipeline also includes TR005, a monoclonal antibody targeting CD47, and several other early-stage programs. The company is backed by prominent venture capital firms and aims to provide innovative treatment options for patients globally.